Clinical Trial

Association Between Early Recurrence and Long-Term Recurrence After Pulsed Field Ablation for Atrial Fibrillation: Prospective Real-World Evidence From China

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated June 16, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to analyze the predictive value of early recurrence within different time windows for late recurrence, ultimately providing evidence-based support for defining the blanking period after pulsed field ablation and stratifying recurrence risk, with the goal of transforming clinical management strategies following pulsed field ablation. The main questions it aims to answer are: 1. Employ big data analysis methods to develop a risk stratification tool for atrial fibrillation; 2. Identify high-risk prognostic indicators for atrial fibrillation and establish early assessment models for short-term and long-term prognosis. Participants will undergo pulsed field ablation for the treatment of atrial fibrillation and will receive structured follow-ups at 1, 3, 6, and 12 months post-ablation. At each follow-up, a 24-hour Holter monitor will be performed to systematically assess the recurrence of atrial arrhythmias and the atrial arrhythmia burden.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-01.
Trial Details
NCT Number NCT07518966
Lead Sponsor West China Hospital
Conditions Atrial Fibrillation (AF)
Enrollment 1,200 participants
Start Date 2025-06-16
Primary Completion 2026-06-16 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-15